<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35052414</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2073-4425</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Genes</Title>
          <ISOAbbreviation>Genes (Basel)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Preclinical Research in McArdle Disease: A Review of Research Models and Therapeutic Strategies.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">74</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/genes13010074</ELocationID>
        <Abstract>
          <AbstractText>McArdle disease is an autosomal recessive disorder of muscle glycogen metabolism caused by pathogenic mutations in the <i>PYGM</i> gene, which encodes the skeletal muscle-specific isoform of glycogen phosphorylase. Clinical symptoms are mainly characterized by transient acute "crises" of early fatigue, myalgia and contractures, which can be accompanied by rhabdomyolysis. Owing to the difficulty of performing mechanistic studies in patients that often rely on invasive techniques, preclinical models have been used for decades, thereby contributing to gain insight into the pathophysiology and pathobiology of human diseases. In the present work, we describe the existing in vitro and in vivo preclinical models for McArdle disease and review the insights these models have provided. In addition, despite presenting some differences with the typical patient's phenotype, these models allow for a deep study of the different features of the disease while representing a necessary preclinical step to assess the efficacy and safety of possible treatments before they are tested in patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Villarreal-Salazar</LastName>
            <ForeName>Mónica</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-8794-691X</Identifier>
            <AffiliationInfo>
              <Affiliation>Mitochondrial and Neuromuscular Disorders Unit, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brull</LastName>
            <ForeName>Astrid</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-3012-451X</Identifier>
            <AffiliationInfo>
              <Affiliation>Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nogales-Gadea</LastName>
            <ForeName>Gisela</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Grup de Recerca en Malalties Neuromusculars i Neuropediàtriques, Department of Neurosciences, Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol i Campus Can Ruti, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Andreu</LastName>
            <ForeName>Antoni L</ForeName>
            <Initials>AL</Initials>
            <AffiliationInfo>
              <Affiliation>EATRIS, European Infrastructure for Translational Medicine, 1081 HZ Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martín</LastName>
            <ForeName>Miguel A</ForeName>
            <Initials>MA</Initials>
            <Identifier Source="ORCID">0000-0003-4741-772X</Identifier>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Mitochondrial and Neuromuscular Diseases Laboratory, 12 de Octubre Hospital Research Institute (i+12), 28041 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arenas</LastName>
            <ForeName>Joaquín</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Mitochondrial and Neuromuscular Diseases Laboratory, 12 de Octubre Hospital Research Institute (i+12), 28041 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Santalla</LastName>
            <ForeName>Alfredo</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-9418-0564</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Sport Sciences, Universidad Pablo de Olavide, 41013 Sevilla, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lucia</LastName>
            <ForeName>Alejandro</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Sport Sciences, European University, 28670 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vissing</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Krag</LastName>
            <ForeName>Thomas O</ForeName>
            <Initials>TO</Initials>
            <Identifier Source="ORCID">0000-0001-9330-668X</Identifier>
            <AffiliationInfo>
              <Affiliation>Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pinós</LastName>
            <ForeName>Tomàs</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Mitochondrial and Neuromuscular Disorders Unit, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Genes (Basel)</MedlineTA>
        <NlmUniqueID>101551097</NlmUniqueID>
        <ISSNLinking>2073-4425</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006012" MajorTopicYN="N">Glycogen Storage Disease Type V</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">McArdle disease</Keyword>
        <Keyword MajorTopicYN="Y">glycogen</Keyword>
        <Keyword MajorTopicYN="Y">glycogen phosphorylase</Keyword>
        <Keyword MajorTopicYN="Y">research models</Keyword>
        <Keyword MajorTopicYN="Y">treatments</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>21</Day>
          <Hour>1</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35052414</ArticleId>
        <ArticleId IdType="pmc">PMC8774685</ArticleId>
        <ArticleId IdType="doi">10.3390/genes13010074</ArticleId>
        <ArticleId IdType="pii">genes13010074</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>McArdle B. Myopathy due to a defect in muscle glycogen breakdown. Clin. Sci. 1951;10:13–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24540673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucia A., Ruiz J.R., Santalla A., Nogales-Gadea G., Rubio J.C., Garcia-Consuegra I., Cabello A., Pérez M., Teijeira S., Vieitez I., et al.  Genotypic and phenotypic features of McArdle disease: Insights from the Spanish national registry. J. Neurol. Neurosurg. Psychiatry. 2012;83:322–328. doi: 10.1136/jnnp-2011-301593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2011-301593</ArticleId>
            <ArticleId IdType="pubmed">22250184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vissing J., Haller R.G. The effect of oral sucrose on exercise tolerance in patients with McArdle’s disease. N. Engl. J. Med. 2003;349:2503–2509. doi: 10.1056/NEJMoa031836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa031836</ArticleId>
            <ArticleId IdType="pubmed">14695410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nogales-Gadea G., Santalla A., Brull A., de Luna N., Lucia A., Pinos T. The pathogenomics of McArdle disease--genes, enzymes, models, and therapeutic implications. J. Inherit. Metab. Dis. 2015;38:221–230. doi: 10.1007/s10545-014-9743-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10545-014-9743-2</ArticleId>
            <ArticleId IdType="pubmed">25053163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uhlén M., Fagerberg L., Hallström B.M., Lindskog C., Oksvold P., Mardinoglu A., Sivertsson Å., Kampf C., Sjöstedt E., Asplund A., et al.  Proteomics. Tissue-Based Map of the Human Proteome. Science. 2015;347:1260419. doi: 10.1126/science.1260419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1260419</ArticleId>
            <ArticleId IdType="pubmed">25613900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Migocka-Patrzalek M., Elias M. Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease. Cells. 2021;10:883.  doi: 10.3390/cells10040883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells10040883</ArticleId>
            <ArticleId IdType="pmc">PMC8070155</ArticleId>
            <ArticleId IdType="pubmed">33924466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmid H., Dolderer B., Thiess U., Verleysdonk S., Hamprecht B. Renal expression of the brain and muscle isoforms of glycogen phosphorylase in different cell types. Neurochem. Res. 2008;33:2575–2582. doi: 10.1007/s11064-008-9640-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11064-008-9640-x</ArticleId>
            <ArticleId IdType="pubmed">18338248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abugessaisa I., Noguchi S., Hasegawa A., Harshbarger J., Kondo A., Lizio M., Severin J., Carninci P., Kawaji H., Kasukawa T. FANTOM5 CAGE profiles of human and mouse reprocessed for GRCh38 and GRCm38 genome assemblies. Sci. Data. 2017;4:170107. doi: 10.1038/sdata.2017.107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sdata.2017.107</ArticleId>
            <ArticleId IdType="pmc">PMC5574367</ArticleId>
            <ArticleId IdType="pubmed">28850105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llavero F., Montoro M.L., Sastre A.A., Fernández-Moreno D., Lacerda H.M., Parada L.A., Lucia A., Zugaza J.L. Epidermal growth factor receptor controls glycogen phosphorylase in T cells through small GTPases of the RAS family. J. Biol. Chem. 2019;294:4345–4358. doi: 10.1074/jbc.RA118.005997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.RA118.005997</ArticleId>
            <ArticleId IdType="pmc">PMC6433075</ArticleId>
            <ArticleId IdType="pubmed">30647127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsujino S., Shanske S., Nonaka I., Di Mauro S. The molecular genetic basis of myophosphorylase deficiency (McArdle’s disease) Muscle Nerve Suppl. 1995;3:S23–S27. doi: 10.1002/mus.880181407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.880181407</ArticleId>
            <ArticleId IdType="pubmed">7603523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nogales-Gadea G., Brull A., Santalla A., Andreu A.L., Arenas J., Martin M.A., Lucia A., de Luna N., Pinós T. McArdle Disease: Update of Reported Mutations and Polymorphisms in the PYGM Gene. Hum. Mutat. 2015;36:669–678. doi: 10.1002/humu.22806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/humu.22806</ArticleId>
            <ArticleId IdType="pubmed">25914343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrou P., Pantzaris M., Dionysiou M., Drousiotou A., Kyriakides T. Minimally symptomatic mcardle disease, expanding the genotype-phenotype spectrum. Muscle Nerve. 2015;52:891–895. doi: 10.1002/mus.24716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.24716</ArticleId>
            <ArticleId IdType="pubmed">26032558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Consuegra I., Blázquez A., Rubio J.C., Arenas J., Ballester-Lopez A., González-Quintana A., Andreu A.L., Pinós T., Coll-Cantí J., Lucia A., et al.  Taking advantage of an old concept, “illegitimate transcription”, for a proposed novel method of genetic diagnosis of McArdle disease. Genet. Med. 2016;18:1128–1135. doi: 10.1038/gim.2015.219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/gim.2015.219</ArticleId>
            <ArticleId IdType="pubmed">26913921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheraud C., Froissart R., Lannes B., Echaniz-Laguna A. Novel variant in the PYGM gene causing late-onset limb-girdle myopathy, ptosis, and camptocormia. Muscle Nerve. 2018;57:157–160. doi: 10.1002/mus.25588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.25588</ArticleId>
            <ArticleId IdType="pubmed">28120463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inal-Gültekin G., Toptaş-Hekimoğlu B., Görmez Z., Gelişin Ö., Durmuş H., Ergüner B., Demirci H., Sağıroğlu M.Ş., Parman Y., Deymeer F., et al.  Myophosphorylase (PYGM) mutations determined by next generation sequencing in a cohort from Turkey with McArdle disease. Neuromuscul. Disord. 2017;27:997–1008. doi: 10.1016/j.nmd.2017.06.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2017.06.004</ArticleId>
            <ArticleId IdType="pmc">PMC5698850</ArticleId>
            <ArticleId IdType="pubmed">28967462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santalla A., Nogales-Gadea G., Encinar A.B., Vieitez I., González-Quintana A., Serrano-Lorenzo P., Consuegra I.G., Asensio S., Ballester-Lopez A., Pintos-Morell G., et al.  Genotypic and phenotypic features of all Spanish patients with McArdle disease: A 2016 update. BMC Genom. 2017;18:819.  doi: 10.1186/s12864-017-4188-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12864-017-4188-2</ArticleId>
            <ArticleId IdType="pmc">PMC5688471</ArticleId>
            <ArticleId IdType="pubmed">29143597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nabavi Nouri M., Lamhonwah A.M., Tein I. Novel myophosphorylase mutation (p.Arg94Pro) with progressive exercise intolerance. Clin. Case Rep. 2018;6:499–501. doi: 10.1002/ccr3.1233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ccr3.1233</ArticleId>
            <ArticleId IdType="pmc">PMC5838269</ArticleId>
            <ArticleId IdType="pubmed">29531726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahroo O.A., Khan K.N., Wright G., Ockrim Z., Scalco R.S., Robson A.G., Tufail A., Michaelides M., Quinlivan R., Webster A.R. Retinopathy Associated with Biallelic Mutations in PYGM (McArdle Disease) Ophthalmology. 2019;126:320–322. doi: 10.1016/j.ophtha.2018.09.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2018.09.013</ArticleId>
            <ArticleId IdType="pmc">PMC6347563</ArticleId>
            <ArticleId IdType="pubmed">30316539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lorenzoni P.J., Werneck L.C., Kay C.S.K., Arndt R.C., Silvado C.E.S., Scola R.H. Single-centre experience on genotypic and phenotypic features of southern Brazilian patients with McArdle disease. Acta Neurol. Belg. 2020;120:303–311. doi: 10.1007/s13760-018-1038-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13760-018-1038-1</ArticleId>
            <ArticleId IdType="pubmed">30415384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satoh A., Hirashio S., Arima T., Yamada Y., Irifuku T., Ishibashi H., Motoda A., Sueda Y., Masaki T. Novel Asp511Thr mutation in McArdle disease with acute kidney injury caused by rhabdomyolysis. CEN Case Rep. 2019;8:194–199. doi: 10.1007/s13730-019-00392-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13730-019-00392-6</ArticleId>
            <ArticleId IdType="pmc">PMC6620219</ArticleId>
            <ArticleId IdType="pubmed">30900170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomes C.P., da Silva A.M.S., Zanoteli E., Pesquero J.B. A new mutation in PYGM causing McArdle disease in a Brazilian patient. Acta Neurol. Belg. 2020;120:705–707. doi: 10.1007/s13760-019-01159-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13760-019-01159-7</ArticleId>
            <ArticleId IdType="pubmed">31175620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie R.R., Yang Y.B., Jin P. Identification of a novel PYGM mutation in a McArdle disease patient misdiagnosed as hypokalemic periodic paralysis. J. Endocrinol. Investig. 2020;43:697–698. doi: 10.1007/s40618-020-01202-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-020-01202-y</ArticleId>
            <ArticleId IdType="pubmed">32100198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chocair P.R., Mohrbacher S., Neves P.D.M.D.M., Pereira L.V.B., Oliveira E.S., Nardotto L.L., Bales A.M., Sato V.A.H., Silva S.N., Ferreira B.M.C., et al.  An elderly diabetic patient with McArdle disease and recurrent rhabdomyolysis: A potential association with late hypoinsulinemia? BMC Geriatr. 2020;20:451. doi: 10.1186/s12877-020-01812-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12877-020-01812-4</ArticleId>
            <ArticleId IdType="pmc">PMC7644386</ArticleId>
            <ArticleId IdType="pubmed">33153458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang J.H., Park J.H., Park J.S., Lee S.K., Lee S., Baik H.W. Molecular diagnosis of McArdle disease using whole-exome sequencing. Exp. Ther. Med. 2021;22:1029. doi: 10.3892/etm.2021.10461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/etm.2021.10461</ArticleId>
            <ArticleId IdType="pmc">PMC8343624</ArticleId>
            <ArticleId IdType="pubmed">34373715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pizzamiglio C., Mahroo O.A., Khan K.N., Patasin M., Quinlivan R. Phenotype and genotype of 197 British patients with McArdle disease: An observational single-centre study. J. Inherit. Metab. Dis. 2021;44:1409–1418. doi: 10.1002/jimd.12438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jimd.12438</ArticleId>
            <ArticleId IdType="pubmed">34534370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quinlivan R., Buckley J., James M., Twist A., Ball S., Duno M., Vissing J., Bruno C., Cassandrini D., Roberts M., et al.  McArdle disease: A clinical review. J. Neurol. Neurosurg. Psychiatry. 2010;81:1182–1188. doi: 10.1136/jnnp.2009.195040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2009.195040</ArticleId>
            <ArticleId IdType="pubmed">20861058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruno C., Cassandrini D., Martinuzzi A., Toscano A., Moggio M., Morandi L., Servidei S., Mongini T., Angelini C., Musumeci O., et al.  McArdle disease: The mutation spectrum of PYGM in a large Italian cohort. Hum. Mutat. 2006;27:718. doi: 10.1002/humu.9434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/humu.9434</ArticleId>
            <ArticleId IdType="pubmed">16786513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartram C., Edwards R.H., Clague J., Beynon R.J. McArdle’s disease: A nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases. Hum. Mol. Genet. 1993;2:1291–1293. doi: 10.1093/hmg/2.8.1291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/2.8.1291</ArticleId>
            <ArticleId IdType="pubmed">8401511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Schahawi M., Tsujino S., Shanske S., Di Mauro S. Diagnosis of McArdle’s disease by molecular genetic analysis of blood. Neurology. 1996;47:579–580. doi: 10.1212/WNL.47.2.579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.47.2.579</ArticleId>
            <ArticleId IdType="pubmed">8757044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martín M.Á., Rubio J.C., Wevers R., Van Engelen B.G.M., Steenbergen G.C.H., Van Diggelen O.P., De Visser M., De Die-Smulders C., Blazquez A., Andreu A.L., et al.  Molecular Analysis of Myophosphorylase Deficiency in Dutch Patients with McArdle’s Disease. Ann. Hum. Genet. 2004;68:17–22. doi: 10.1046/j.1529-8817.2003.00067.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1529-8817.2003.00067.x</ArticleId>
            <ArticleId IdType="pubmed">14748827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aquaron R., Berge-Lefranc J.L., Pellissier J.F., Montfort M.F., Mayan M., Figarella-Branger D., Coquet M., Serratrice G., Pouget J. Molecular characterization of myophosphorylase deficiency (McArdle disease) in 34 patients from Southern France: Identification of 10 new mutations. Absence of genotype-phenotype correlation. Neuromuscul. Disord. NMD. 2007;17:235–241. doi: 10.1016/j.nmd.2006.12.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2006.12.014</ArticleId>
            <ArticleId IdType="pubmed">17324573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gurgel-Giannetti J., Nogales-Gadea G., van der Linden H., Jr., Bellard T.M., Brasileiro Filho G., Giannetti A.V., de Castro Concentino E.L., Vainzof M. Clinical and molecular characterization of McArdle’s disease in Brazilian patients. Neuromol. Med. 2013;15:470–475. doi: 10.1007/s12017-013-8233-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12017-013-8233-2</ArticleId>
            <ArticleId IdType="pubmed">23653251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deschauer M., Morgenroth A., Joshi P.R., Glaser D., Chinnery P.F., Aasly J., Schreiber H., Knape M., Zierz S., Vorgerd M. Analysis of spectrum and frequencies of mutations in McArdle disease. J. Neurol. 2007;254:797–802. doi: 10.1007/s00415-006-0447-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-006-0447-x</ArticleId>
            <ArticleId IdType="pubmed">17404776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin M.A., Rubio J.C., Buchbinder J., Fernandez-Hojas R., del Hoyo P., Teijeira S., Gámez J., Navarro C., Fernández J.M., Cabello A., et al.  Molecular heterogeneity of myophosphorylase deficiency (McArdle’s disease): A genotype-phenotype correlation study. Ann. Neurol. 2001;50:574–581. doi: 10.1002/ana.1225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.1225</ArticleId>
            <ArticleId IdType="pubmed">11706962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinuzzi A., Sartori E., Fanin M., Nascimbeni A., Valente L., Angelini C., Siciliano G., Mongini T., Tonin P., Tomelleri G., et al.  Phenotype modulators in myophosphorylase deficiency. Ann. Neurol. 2003;53:497–502. doi: 10.1002/ana.10499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10499</ArticleId>
            <ArticleId IdType="pubmed">12666117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paradas C., Fernandez-Cadenas I., Gallardo E., Llige D., Arenas J., Illa I., Andreu A.L. Variable presentation of the clinical phenotype of McArdle’s disease in a kindred harbouring a novel compound genotype in the muscle glycogen phosphorylase gene. Neurosci. Lett. 2005;391:28–31. doi: 10.1016/j.neulet.2005.08.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2005.08.026</ArticleId>
            <ArticleId IdType="pubmed">16154688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucia A., Nogales-Gadea G., Perez M., Martin M.A., Andreu A.L., Arenas J. McArdle disease: What do neurologists need to know? Nat. Clin. Pract. Neurol. 2008;4:568–577. doi: 10.1038/ncpneuro0913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncpneuro0913</ArticleId>
            <ArticleId IdType="pubmed">18833216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Preisler N., Cohen J., Vissing C.R., Madsen K.L., Heinicke K., Sharp L.J., Phillips L., Romain N., Park S.Y., Newby M., et al.  Impaired glycogen breakdown and synthesis in phosphoglucomutase 1 deficiency. Mol. Genet. Metab. 2017;122:117–121. doi: 10.1016/j.ymgme.2017.08.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymgme.2017.08.007</ArticleId>
            <ArticleId IdType="pubmed">28882528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santalla A., Nogales-Gadea G., Ortenblad N., Brull A., de Luna N., Pinos T., Phillips L., Romain N., Park S.Y., Newby M., et al.  McArdle disease: A unique study model in sports medicine. Sports Med. 2014;44:1531–1544. doi: 10.1007/s40279-014-0223-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40279-014-0223-5</ArticleId>
            <ArticleId IdType="pubmed">25028051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brull A., de Luna N., Blanco-Grau A., Lucia A., Martin M.A., Arenas J., Lucia A. Phenotype consequences of myophosphorylase dysfunction: Insights from the McArdle mouse model. J. Physiol. 2015;593:2693–2706. doi: 10.1113/JP270085.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/JP270085</ArticleId>
            <ArticleId IdType="pmc">PMC4500353</ArticleId>
            <ArticleId IdType="pubmed">25873271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angelos S., Valberg S.J., Smith B.P., McQuarrie P.S., Shanske S., Tsujino S., DiMauro S., Cardinet G.H. Myophosphorylase deficiency associated with rhabdomyolysis and exercise intolerance in 6 related charolais cattle. Muscle Nerve. 1995;18:736–740. doi: 10.1002/mus.880180710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.880180710</ArticleId>
            <ArticleId IdType="pubmed">7783763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsujino S., Shanske S., Valberg S.J., Cardinet G.H., 3rd, Smith B.P., Di Mauro S. Cloning of bovine muscle glycogen phosphorylase cDNA and identification of a mutation in cattle with myophosphorylase deficiency, an animal model for McArdle’s disease. Neuromuscul. Disord. NMD. 1996;6:19–26. doi: 10.1016/0960-8966(95)00014-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0960-8966(95)00014-3</ArticleId>
            <ArticleId IdType="pubmed">8845714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan P., Allen J.G., Wilton S.D., Akkari P.A., Huxtable C.R., Laing N.G. A splice-site mutation causing ovine McArdle’s disease. Neuromuscul. Disord. NMD. 1997;7:336–342. doi: 10.1016/S0960-8966(97)00062-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0960-8966(97)00062-X</ArticleId>
            <ArticleId IdType="pubmed">9267848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nogales-Gadea G., Pinós T., Lucia A., Arenas J., Cámara Y., Brull A., De Luna N., Martín M.A., Garcia-Arumí E., Marti R., et al.  Knock-in mice for the R50X mutation in the PYGM gene present with McArdle disease. Brain. 2012;135:2048–2057. doi: 10.1093/brain/aws141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aws141</ArticleId>
            <ArticleId IdType="pubmed">22730558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Migocka-Patrzalek M., Lewicka A., Elias M., Daczewska M. The effect of muscle glycogen phosphorylase (Pygm) knockdown on zebrafish morphology. Int. J. Biochem. Cell Biol. 2020;118:105658. doi: 10.1016/j.biocel.2019.105658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biocel.2019.105658</ArticleId>
            <ArticleId IdType="pubmed">31747538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howell J.M., Walker K.R., Creed K.E., Dunton E., Davies L., Quinlivan R., Karpati G. Phosphorylase re-expression, increase in the force of contraction and decreased fatigue following notexin-induced muscle damage and regeneration in the ovine model of McArdle disease. Neuromuscul. Disord. NMD. 2014;24:167–177. doi: 10.1016/j.nmd.2013.10.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2013.10.003</ArticleId>
            <ArticleId IdType="pubmed">24309536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krag T.O., Pinos T., Nielsen T.L., Brull A., Andreu A.L., Vissing J. Differential Muscle Involvement in Mice and Humans Affected by McArdle Disease. J. Neuropathol. Exp. Neurol. 2016;75:441–454. doi: 10.1093/jnen/nlw018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnen/nlw018</ArticleId>
            <ArticleId IdType="pubmed">27030740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Real-Martinez A., Brull A., Huerta J., Tarrasó G., Lucia A., Martin M., Arenas J., Andreu A.L., Nogales-Gadea G., Vissing J., et al.  Low survival rate and muscle fiber-dependent aging effects in the McArdle disease mouse model. Sci. Rep. 2019;9:5116. doi: 10.1038/s41598-019-41414-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-41414-8</ArticleId>
            <ArticleId IdType="pmc">PMC6435661</ArticleId>
            <ArticleId IdType="pubmed">30914683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almodovar-Paya A., Villarreal-Salazar M., de Luna N., Nogales-Gadea G., Real-Martinez A., Andreu A.L., Martín M.A., Arenas J., Lucia A., Vissing J., et al.  Preclinical Research in Glycogen Storage Diseases: A Comprehensive Review of Current Animal Models. Int. J. Mol. Sci. 2020;21:9621.  doi: 10.3390/ijms21249621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21249621</ArticleId>
            <ArticleId IdType="pmc">PMC7766110</ArticleId>
            <ArticleId IdType="pubmed">33348688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nielsen J.N., Wojtaszewski J.F.P., Haller R.G., Hardie D.G., Kemp B.E., Richter E.A., Vissing J. Role of 5′AMP-activated protein kinase in glycogen synthase activity and glucose utilization: Insights from patients with McArdle’s disease. J. Physiol. 2002;541:979–989. doi: 10.1113/jphysiol.2002.018044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.2002.018044</ArticleId>
            <ArticleId IdType="pmc">PMC2290379</ArticleId>
            <ArticleId IdType="pubmed">12068056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mineo I., Kono N., Shimizu T., Hara N., Yamada Y., Sumi S., Nonaka K., Tarui S. Excess purine degradation in exercising muscles of patients with glycogen storage disease types V and VII. J. Clin. Investig. 1985;76:556–560. doi: 10.1172/JCI112006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI112006</ArticleId>
            <ArticleId IdType="pmc">PMC423860</ArticleId>
            <ArticleId IdType="pubmed">3861621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brooke M.H., Patterson V.H., Kaiser K.K. Hypoxanthine and Mcardle disease: A clue to metabolic stress in the working forearm. Muscle Nerve. 1983;6:204–206. doi: 10.1002/mus.880060307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.880060307</ArticleId>
            <ArticleId IdType="pubmed">6574314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubio J.C., Pérez M., Maté-Muñoz J.L., García-Consuegra I., Chamorro-Viña C., Del Valle M.F., Andreu A.L., Martin M.A., Arenas J., Lucia A. AMPD1 Genotypes and Exercise Capacity in McArdle Patients. Int. J. Sports Med. 2007;29:331–335. doi: 10.1055/s-2007-965358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-2007-965358</ArticleId>
            <ArticleId IdType="pubmed">17687759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nielsen T.L., Pinós T., Brull A., Vissing J., Krag T.O. Exercising with blocked muscle glycogenolysis: Adaptation in the McArdle mouse. Mol. Genet. Metab. 2018;123:21–27. doi: 10.1016/j.ymgme.2017.11.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymgme.2017.11.006</ArticleId>
            <ArticleId IdType="pubmed">29174367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohn T.A., Noakes T.D., Rae D.E., Rubio J.C., Santalla A., Nogales-Gadea G., Pinós T., Martín M.A., Arenas J., Lucia A. McArdle disease does not affect skeletal muscle fibre type profiles in humans. Biol. Open. 2014;3:1224–1227. doi: 10.1242/bio.20149548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/bio.20149548</ArticleId>
            <ArticleId IdType="pmc">PMC4265760</ArticleId>
            <ArticleId IdType="pubmed">25432515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy R.M., Xu H., Latchman H., Larkins N.T., Gooley P.R., Stapleton D.I. Single fiber analyses of glycogen-related proteins reveal their differential association with glycogen in rat skeletal muscle. Am. J. Physiol. Cell Physiol. 2012;303:C1146–C1155. doi: 10.1152/ajpcell.00252.2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpcell.00252.2012</ArticleId>
            <ArticleId IdType="pubmed">23015546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krag T.O., Pinós T., Nielsen T.L., Duran J., Garcia-Rocha M., Andreu A.L., Vissing J. Differential glucose metabolism in mice and humans affected by McArdle disease. Am. J. Physiol. Integr. Comp. Physiol. 2016;311:R307–R314. doi: 10.1152/ajpregu.00489.2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpregu.00489.2015</ArticleId>
            <ArticleId IdType="pubmed">27280431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiuza-Luces C., Nogales-Gadea G., Garcia-Consuegra I., Pareja-Galeano H., Rufian-Vazquez L., Perez L.M., Andreu A.L., Arenas J., Martín M.A., Pinós T., et al.  Muscle Signaling in Exercise Intolerance: Insights from the McArdle Mouse Model. Med. Sci. Sports Exerc. 2016;48:1448–1458. doi: 10.1249/MSS.0000000000000931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1249/MSS.0000000000000931</ArticleId>
            <ArticleId IdType="pubmed">27031745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Stefano N., Argov Z., Matthews P.M., Karpati G., Arnold D.L. Impairment of muscle mitochondrial oxidative metabolism in McArdles’s disease. Muscle Nerve. 1996;19:764–769. doi: 10.1002/(SICI)1097-4598(199606)19:6&lt;764::AID-MUS12&gt;3.0.CO;2-L.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-4598(199606)19:6&lt;764::AID-MUS12&gt;3.0.CO;2-L</ArticleId>
            <ArticleId IdType="pubmed">8609928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitaoka Y., Ogborn D.I., Nilsson M.I., Mocellin N.J., MacNeil L.G., Tarnopolsky M.A. Oxidative stress and Nrf2 signaling in McArdle disease. Mol. Genet. Metab. 2013;110:297–302. doi: 10.1016/j.ymgme.2013.06.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymgme.2013.06.022</ArticleId>
            <ArticleId IdType="pubmed">23906480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaczor J.J., Robertshaw H.A., Tarnopolsky M.A. Higher oxidative stress in skeletal muscle of McArdle disease patients. Mol. Genet. Metab. Rep. 2017;12:69–75. doi: 10.1016/j.ymgmr.2017.05.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymgmr.2017.05.009</ArticleId>
            <ArticleId IdType="pmc">PMC5470535</ArticleId>
            <ArticleId IdType="pubmed">28649515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nogales-Gadea G., Consuegra-García I., Rubio J.C., Arenas J., Cuadros M., Cámara Y., Torres-Torronteras J., Fiuza-Luces C., Lucia A., Martín M.A., et al.  A Transcriptomic Approach to Search for Novel Phenotypic Regulators in McArdle Disease. PLoS ONE. 2012;7:e31718.  doi: 10.1371/journal.pone.0031718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0031718</ArticleId>
            <ArticleId IdType="pmc">PMC3276513</ArticleId>
            <ArticleId IdType="pubmed">22347505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiuza-Luces C., Santos-Lozano A., Llavero F., Campo R., Nogales-Gadea G., Díez-Bermejo J., Baladrón C., González-Murillo Á., Arenas J., Martín M.A., et al.  Muscle molecular adaptations to endurance exercise training are conditioned by glycogen availability: A proteomics-based analysis in the McArdle mouse model. J. Physiol. 2018;596:1035–1061. doi: 10.1113/JP275292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/JP275292</ArticleId>
            <ArticleId IdType="pmc">PMC5851888</ArticleId>
            <ArticleId IdType="pubmed">29315579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinuzzi A., Vergani L., Carrozzo R., Fanin M., Bartoloni L., Angelini C., Engel W.K. Expression of muscle-type phosphorylase in innervated and aneural cultured muscle of patients with myophosphorylase deficiency. J. Clin. Investig. 1993;92:1774–1780. doi: 10.1172/JCI116766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI116766</ArticleId>
            <ArticleId IdType="pmc">PMC288339</ArticleId>
            <ArticleId IdType="pubmed">8408630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meienhofer M.C., Askanas V., Proux-Daegelen D., Dreyfus J.C., Engel W.K. Muscle-type phosphorylase activity present in muscle cells cultured from three patients with myophosphorylase deficiency. Arch. Neurol. 1977;34:779–781. doi: 10.1001/archneur.1977.00500240067013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1977.00500240067013</ArticleId>
            <ArticleId IdType="pubmed">588100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nogales-Gadea G., Mormeneo E., Garcia-Consuegra I., Rubio J.C., Orozco A., Arenas J., Martín M.A., Lucia A., Gomez-Foix A.M., Marti R., et al.  Expression of glycogen phosphorylase isoforms in cultured muscle from patients with McArdle’s disease carrying the p.R771PfsX33 PYGM mutation. PLoS ONE. 2010;5:e13164.  doi: 10.1371/journal.pone.0013164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0013164</ArticleId>
            <ArticleId IdType="pmc">PMC2950139</ArticleId>
            <ArticleId IdType="pubmed">20957198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Luna N., Brull A., Guiu J.M., Lucia A., Martín M.Á., Arenas J., Martí R., Andreu A.L., Pinós T. Sodium valproate increases the brain isoform of glycogen phosphorylase: Looking for a compensation mechanism in McArdle disease using a mouse primary skeletal-muscle culture in vitro. Dis. Model. Mech. 2015;8:467–472. doi: 10.1242/dmm.020230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dmm.020230</ArticleId>
            <ArticleId IdType="pmc">PMC4415898</ArticleId>
            <ArticleId IdType="pubmed">25762569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howell J.M., Dunton E., Creed K.E., Quinlivan R., Sewry C. Investigating sodium valproate as a treatment for McArdle disease in sheep. Neuromuscul. Disord. NMD. 2015;25:111–119. doi: 10.1016/j.nmd.2014.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2014.10.002</ArticleId>
            <ArticleId IdType="pubmed">25455802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris J.B., Johnson M.A. Further observations on the pathological responses of rat skeletal muscle to toxins isolated from the venom of the Australian tiger snake, Notechis scutatus scutatus. Clin. Exp. Pharmacol. Physiol. 1978;5:587–600. doi: 10.1111/j.1440-1681.1978.tb00714.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1681.1978.tb00714.x</ArticleId>
            <ArticleId IdType="pubmed">152684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharp N.J., Kornegay J.N., Bartlett R.J., Hung W.Y., Dykstra M.J. Notexin-induced muscle injury in the dog. J. Neurol. Sci. 1993;116:73–81. doi: 10.1016/0022-510X(93)90092-D.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-510X(93)90092-D</ArticleId>
            <ArticleId IdType="pubmed">8509806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Numata S., Ye T., Hyde T.M., Guitart-Navarro X., Tao R., Wininger M., Colantuoni C., Weinberger D.R., Kleinman J.E., Lipska B.K. DNA methylation signatures in development and aging of the human prefrontal cortex. Am. J. Hum. Genet. 2012;90:260–272. doi: 10.1016/j.ajhg.2011.12.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajhg.2011.12.020</ArticleId>
            <ArticleId IdType="pmc">PMC3276664</ArticleId>
            <ArticleId IdType="pubmed">22305529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Detich N., Bovenzi V., Szyf M. Valproate induces replication-independent active DNA demethylation. J. Biol. Chem. 2003;278:27586–27592. doi: 10.1074/jbc.M303740200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M303740200</ArticleId>
            <ArticleId IdType="pubmed">12748177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarrasó G., Real-Martinez A., Parés M., Romero-Cortadellas L., Puigros L., Moya L., de Luna N., Brull A., Martín M.A., Arenas J., et al.  Absence of p.R50X Pygm read-through in McArdle disease cellular models. Dis. Model. Mech. 2020;13:043281. doi: 10.1242/dmm.043281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dmm.043281</ArticleId>
            <ArticleId IdType="pmc">PMC6994938</ArticleId>
            <ArticleId IdType="pubmed">31848135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howell J.M., Walker K.R., Davies L., Dunton E., Everaardt A., Laing N., Karpati G. Adenovirus and adeno-associated virus-mediated delivery of human myophosphorylase cDNA and LacZ cDNA to muscle in the ovine model of McArdle’s disease: Expression and re-expression of glycogen phosphorylase. Neuromuscul. Disord. NMD. 2008;18:248–258. doi: 10.1016/j.nmd.2007.10.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2007.10.006</ArticleId>
            <ArticleId IdType="pubmed">18343113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNamara E.L., Taylor R.L., Clayton J., Goullee H., Dilworth K.L., Pinós T., Brull A., Alexander I.E., Lisowski L., Ravenscroft G., et al.  Systemic AAV8-mediated delivery of a functional copy of muscle glycogen phosphorylase (Pygm) ameliorates disease in a murine model of McArdle disease. Hum. Mol. Genet. 2019;29:20–30. doi: 10.1093/hmg/ddz214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddz214</ArticleId>
            <ArticleId IdType="pubmed">31511858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scalco R.S., Stemmerik M., Løkken N., Vissing C.R., Madsen K.L., Michalak Z., Pattni J., Godfrey R., Samandouras G., Bassett P., et al.  Results of an open label feasibility study of sodium valproate in people with McArdle disease. Neuromuscul. Disord. 2020;30:734–741. doi: 10.1016/j.nmd.2020.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2020.04.009</ArticleId>
            <ArticleId IdType="pubmed">32811700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroers A., Kley R.A., Stachon A., Horvath R., Lochmuller H., Zange J., Vorgerd M. Gentamicin treatment in McArdle disease: Failure to correct myophosphorylase deficiency. Neurology. 2006;66:285–286. doi: 10.1212/01.wnl.0000194212.31318.fc.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000194212.31318.fc</ArticleId>
            <ArticleId IdType="pubmed">16434679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vissing J., Duno M., Schwartz M., Haller R.G. Splice mutations preserve myophosphorylase activity that ameliorates the phenotype in McArdle disease. Brain. 2009;132:1545–1552. doi: 10.1093/brain/awp065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awp065</ArticleId>
            <ArticleId IdType="pubmed">19433441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Guiner C., Servais L., Montus M., Larcher T., Fraysse B., Moullec S., Allais M., François V., Dutilleul M., Malerba A., et al.  Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat. Commun. 2017;8:16105. doi: 10.1038/ncomms16105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms16105</ArticleId>
            <ArticleId IdType="pmc">PMC5537486</ArticleId>
            <ArticleId IdType="pubmed">28742067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mack D.L., Poulard K., Goddard M.A., Latournerie V., Snyder J.M., Grange R.W., Elverman M.R., Denard J., Veron P., Buscara L., et al.  Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs. Mol. Ther. 2017;25:839–854. doi: 10.1016/j.ymthe.2017.02.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymthe.2017.02.004</ArticleId>
            <ArticleId IdType="pmc">PMC5383631</ArticleId>
            <ArticleId IdType="pubmed">28237839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elverman M., Goddard M.A., Mack D., Snyder J.M., Lawlor M.W., Meng H., Beggs A., Buj-Bello A., Bs K.P., Marsh A.P., et al.  Long-term effects of systemic gene therapy in a canine model of myotubular myopathy. Muscle Nerve. 2017;56:943–953. doi: 10.1002/mus.25658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.25658</ArticleId>
            <ArticleId IdType="pmc">PMC5620115</ArticleId>
            <ArticleId IdType="pubmed">28370029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aguti S., Malerba A., Zhou H. The progress of AAV-mediated gene therapy in neuromuscular disorders. Expert Opin. Biol. Ther. 2018;18:681–693. doi: 10.1080/14712598.2018.1479739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14712598.2018.1479739</ArticleId>
            <ArticleId IdType="pubmed">29781327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hermann T. Aminoglycoside antibiotics: Old drugs and new therapeutic approaches. Cell. Mol. Life Sci. CMLS. 2007;64:1841–1852. doi: 10.1007/s00018-007-7034-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-007-7034-x</ArticleId>
            <ArticleId IdType="pubmed">17447006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du L., Damoiseaux R., Nahas S., Gao K., Hu H., Pollard J.M., Goldstine J., Jung M.E., Henning S.M., Bertoni C., et al.  Nonaminoglycoside compounds induce readthrough of nonsense mutations. J. Exp. Med. 2009;206:2285–2297. doi: 10.1084/jem.20081940.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20081940</ArticleId>
            <ArticleId IdType="pmc">PMC2757881</ArticleId>
            <ArticleId IdType="pubmed">19770270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birch K.E., Quinlivan R.M., Morris G.E. Cell models for McArdle disease and aminoglycoside-induced read-through of a premature termination codon. Neuromuscul. Disord. NMD. 2013;23:43–51. doi: 10.1016/j.nmd.2012.06.348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2012.06.348</ArticleId>
            <ArticleId IdType="pubmed">22818872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dabrowski M., Bukowy-Bieryllo Z., Zietkiewicz E. Translational readthrough potential of natural termination codons in eucaryotes--The impact of RNA sequence. RNA Biol. 2015;12:950–958. doi: 10.1080/15476286.2015.1068497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15476286.2015.1068497</ArticleId>
            <ArticleId IdType="pmc">PMC4615788</ArticleId>
            <ArticleId IdType="pubmed">26176195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heinicke K., Dimitrov I.E., Romain N., Cheshkov S., Ren J., Malloy C.R., Haller R.G. Reproducibility and Absolute Quantification of Muscle Glycogen in Patients with Glycogen Storage Disease by 13C NMR Spectroscopy at 7 Tesla. PLoS ONE. 2014;9:e108706.  doi: 10.1371/journal.pone.0108706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0108706</ArticleId>
            <ArticleId IdType="pmc">PMC4189928</ArticleId>
            <ArticleId IdType="pubmed">25296331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnstone A.C., McSporran K.D., Kenny J.E., Anderson I.L., Macpherson G.R., Jolly R.D. Myophosphorylase deficiency (glycogen storage disease Type V) in a herd of Charolais cattle in New Zealand: Confirmation by PCR-RFLP testing. N. Z. Vet. J. 2004;52:404–408. doi: 10.1080/00480169.2004.36459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/00480169.2004.36459</ArticleId>
            <ArticleId IdType="pubmed">15768143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brooks E.D., Koeberl D.D. Large animal models and new therapies for glycogen storage disease. J. Inherit. Metab. Dis. 2015;38:505–509. doi: 10.1007/s10545-014-9766-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10545-014-9766-8</ArticleId>
            <ArticleId IdType="pmc">PMC4513910</ArticleId>
            <ArticleId IdType="pubmed">25224826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Girard J., Ferre P., Pegorier J.P., Duee P.H. Adaptations of glucose and fatty acid metabolism during perinatal period and suckling-weaning transition. Physiol. Rev. 1992;72:507–562. doi: 10.1152/physrev.1992.72.2.507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physrev.1992.72.2.507</ArticleId>
            <ArticleId IdType="pubmed">1557431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Castro M., Johnston J., Biesecker L. Determining the prevalence of McArdle disease from gene frequency by analysis of next-generation sequencing data. Genet. Med. Off. J. Am. Coll. Med. Genet. 2015;17:1002–1006. doi: 10.1038/gim.2015.9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/gim.2015.9</ArticleId>
            <ArticleId IdType="pmc">PMC4561039</ArticleId>
            <ArticleId IdType="pubmed">25741863</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
